Abstract:Objective: To screen the possible potential signaling pathways related to enhancer of zeste homolog 2 (EZH2) based on ceRNA mechanism, and to analyze the correlation between E2H2 and depths of various immune cell infiltration depths. The relationship between different immune checkpoints were also analyzed. Methods: First, the expression of EZH2 in pan-cancer (18 malignancies) was analyzed with the TCGA database. Hepatocellular carcinoma (HCC) tissues of 374 cases and normal tissues of 50 cases were analyzed in terms of the differential expression, overall survival (OS) and progression-free-survival (PFS). Then, we conducted GO and KEGG enrichment analysis on target gene. We also analyzed mRNA-miRNA and MicroRNA (miRNA)- long non-coding RNA (lncRNA) correlation with starbase databse, so as to determine the potential ceRNA mechanism associated with EZH2. Finally, immunoassay and drug-sensitivity analysis of EZH2 was performed. Results: Seven potential EZH2-related ceRNA pathways were screened out, namely lncRNA: Small Nucleolar RNA Host Gene 1 (SNHG1), SNHG 3, and SNHG 6-miR-101-3p-EZH2; and lncRNA: Long Intergenic Non-Protein Coding RNA 1978 (LINC01978), SNHG12, Ring Finger Protein 216 Pseudogene 1 (RNF216P1), and Coiled-coil Domain Containing 18 Antisense RNA 1 (CCDC18-AS1)-let-7c-5p-EZH2. Finally, 4 potential EZH2-related ceRNA pathways were identified through qPCR.According to immune correlation analysis, EZH2 may be positively correlated with T cells follicular helper, T cells Cluster of differentiation (CD)4 memory activated, Macrophages M0, and B cells memory (P < 0.05, cof > 0.2); while be negatively correlated with T cells CD4 + memory resting (P < 0.05, cof < -0.2). And EZH2 is positively correlated with Programmed Cell Death 1 (PDCD1) (R = 0.22), CD274 (R = 0.3) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) (R = 0.23). According to drug sensitivity analysis, patients in the high expression group were more susceptible to the effects of various drugs including Sorafenib, 5-Fluorouracil, Doxorubicin, Etoposide, Paclitaxel, and Vinorelbine than those with low expression. Conclusion: This study revealed seven potential pathways of Enhancer of Zeste Homolog 2 (EZH2)-related ceRNA mechanisms: lncRNA (SNHG3, 6) -Mir-101-3P-ezh2; lncRNA (SNHG12, RNF216P1)-let-7c-5p-EZH2. We also analyzed the immunity and drug sensitivity of EZH2. Our study proves that EZH2 still has great research prospects in HCC.

Expression of EZH2 in cervical cancer and its relationship with cell proliferation and angiogenesis

Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.

Morphologic and Molecular Correlates of EZH2 As a Predictor of Platinum Resistance in High-Grade Ovarian Serous Carcinoma.

Prognostic Significance of Histone Methyltransferase Enhancer of Zeste Homolog 2 in Patients with Cervical Squamous Cell Carcinoma

Enhancer of Zeste Homolog 2 is Involved in the Proliferation of Endometrial Carcinoma.

EZH2-mediated Repression of GSK-3β and TP53 Promotes Wnt/β-catenin Signaling-Dependent Cell Expansion in Cervical Carcinoma.

Ezh2-Mediated Repression Of Gsk-3 Beta And Tp53 Promotes Wnt/Beta-Catenin Signaling-Dependent Cell Expansion In Cervical Carcinoma

Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma.

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

Up-regulation of Enhancer of Zeste Homolog 2 is Associated Positively with Cyclin D1 Overexpression and Poor Clinical Outcome in Head and Neck Squamous Cell Carcinoma.

Expression of Vascular Endothelial Growth Factor-C and Its Receptor VEGFR-3 in Cervical Squamous Cell Carcinoma and Its Clinical Significance

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Expression and clinical significance of HER-2 oncogene in cervical lesion cells

The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.

Activation of the CCL22/CCR4 Causing EMT Process Remodeling under EZH2-mediated Epigenetic Regulation in Cervical Carcinoma.

EZH2-mediated Epigenetic Activation of the CCL22/CCR4 Causing EMT Process Remodeling in Cervical Carcinoma

Expression of EZH2 Mrna and Protein in Human Prostate Carcinoma and Its Relationship with Cell Proliferation

Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Clinical and biological significance of EZH2 expression in endometrial cancer